Intra Coronary AdjunctivE Tenecteplase During Primary PCI for STEMI:

Slides:



Advertisements
Similar presentations
J. Mehilli, A. Kastrati, K. Huber, S. Schulz, J. Pache, C.Markwardt, S. Kufner, F. Dotzer, K. Schlotterbeck, J. Dirschinger, A. Schömig. Abciximab in Patients.
Advertisements

Intracoronary Serotonin and Endothelin Release After PCI / Stenting Taylor AJ. Am Heart J Aug;148(2): e10 Leosco et al, AJC 1999;84:
Anterior Depressions Angiographic and Clinical Outcomes Among Patients with Acute Coronary Syndromes Presenting with Anterior ST-Segment Depressions C.
GP IIb/IIIa Inhibition in STEMI: Growing Clinical Trial Evidence.
Prehospital Fibrinolysis with Double Antiplatelet Therapy in Acute ST-Elevation Myocardial Infarction: The Clarity Ambulance Substudy Prehospital Fibrinolysis.
Enhancement of thrombolysis in AMI is an unmet clinical need Increase the rate of reperfusion without increasing bleeding Reduce the time to complete reperfusion.
Intracoronary Eptifibatide Bolus Administration During Percutaneous Coronary Revascularization for Acute Coronary Syndromes With Evaluation of Platelet.
1 PCI in Patients Receiving Enoxaparin or UFH Following Fibrinolytic Therapy for STEMI: PCI ExTRACT-TIMI 25 C. Michael Gibson, Sabina A. Murphy, David.
ARMYDA-5 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Prospective, multicenter, randomized trial investigating influence.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Is PCI necessary for AMI related artery with TIMI 3 flow ? Donghoon Choi Yonsei Cardiovascular Center Yonsei University College of Medicine.
Which Early ST-Elevation Myocardial Infarction Therapy (WEST) Trial Paul W. Armstrong, WEST Steering Committee Published in The European Heart Journal.
Improving outcome of STEMI PCI: Preliminary Results of Crystal AMI trial Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators.
Baran KW August 28, 2000 Kenneth W. Baran MD for the LIMIT AMI Investigators St. Paul Heart Clinic, St. Paul, MN, USA Sponsor: Genentech Inc., South San.
Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial Presented at AHA Scientific Sessions Nov. 15, 2000.
RP Giugliano MD, SM; MT Roe, MD, MHS; RA Harrington MD; CM Gibson, MS, MD; U Zeymer, MD; F Van de Werf, MD, PhD; KW Baran, MD; HP Hobbach, MD; LH Woodlief,
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Germano Di Sciascio, MD, FACC, FESC Professor & Chairman of.
The Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented.
Name of the speaker: Germano DiSciascio I have the following potential conflicts of interest to report:  Consulting  Employment in industry  Stockholder.
Proof of Concept #1: Occluded Arteries Cause Acute MI Proof of Concept #1: Occluded Arteries Cause Acute MI Proof of Concept #2: Drugs (in this case IC.
LESSON 1 LESSON 1 Establishment of:
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
PROTECT: What Have We Learned Lesson 2: TMPG is associated with clinical and biomarker outcomes following PCI.
Randomized Trial to Evaluate the Relative PROTECTion against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Anti-Platelet and Anti-Thrombotic.
The Effect of Cangrelor and Access Site on Ischemic and Bleeding Events – Insights from CHAMPION PHOENIX J. Antonio Gutierrez, MD, MHS, Robert A. Harrington,
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Randomized Early versus Late AbciXimab in Acute Myocardial Infarction treated with primary coronary intervention (RELAx-AMI Trial) Mauro Maioli M.D., Francesco.
High-risk ST elevation MI patients (>4 mm elevation), Sx < 12 hrs 5 PCI centers (n=443) and 22 referring hospitals (n=1,129), transfer in < 3 hrs High-risk.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
SPEED : GUSTO-IV PILOT GUSTO-IV Pilot Trial. SPEED : GUSTO-IV PILOT Rationale for Combination Therapy in AMI Enhance Incidence and Speed of Reperfusion.
Relationship of the TIMI Myocardial Perfusion Grades, Flow Grades, Frame Count, and Percutaneous Coronary Intervention to Long-Term Outcomes After Thrombolytic.
Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented at.
Randomized Early versus Late Abciximab in Acute Myocardial Infarction Treated With Primary Coronary Intervention (RELAx-AMI Trial) Mauro Maioli, MD, Francesco.
1 Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial N Engl J Med 2001;344:
Tirofiban Meta-Analysis
Gregg W. Stone MD for the ACUITY Investigators
The American College of Cardiology Presented by Dr. Adnan Kastrati
TAXUS II: Slow Release Formula An International, Randomized, Multicenter, Blinded Trial of TAXUSTM NIRxTM SR Stent Presented at TCT 2002.
ASSENT-3 PLUS 1,639 patients with STEMI Treatment Group A
The European Society of Cardiology Presented by Dr. Saman Rasoul
Presenter Disclosure Information
Dr. Harvey White on behalf of the ACUITY investigators
ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.
European Society of Cardiology 2003
TAXUS II: Moderate Release Formula An International, Randomized, Multicenter, Blinded Trial of TAXUSTM NIRxTM MR Stent Presented at TCT 2002.
Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction:
PROTECT – TIMI 30 Trial Randomized Trial to Evaluate the Relative PROTECTion against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Anti-Platelet.
Published in the European Heart Journal
American Heart Association Presented by Dr. Julinda Mehilli
Impact of Platelet Reactivity Following Clopidogrel Administration
In STEMI Complete Reperfusion (TFG 3, TMPG 3, ST Res  70%) is Associated with a Greater Percent of Receptors Occupied by Integrilin 52.0% % Pts With Complete.
Myocardial Staining (TMPG 1)  Post-Stent in AMI
Erasmus MC, Thoraxcenter
52.0% Complete Resolution TFG 3 TMPG 3 ST Resolution  70% p=0.006
Emerging Data Regarding the Potential Benefits of Early Initiation of Clopidogrel Among ACS Patients C. Michael Gibson, M.S., M.D.
Secondary Efficacy Endpoints
Implications of Preoperative Thienopyridine Use
Dye strongly persistent
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Infarct Size after Primary Angioplasty Patients With Bivalirudin
Update on the New Antiplatelet Agents:
Angioplasty Balloon-associated Coronary Debris and the EZ FilterWire
Dye strongly persistent
Association of Troponin Elevation with Risk of Mortality in Acute Coronary Syndromes Mortality at 42 Days  % A study by Antman and.
European Heart Journal Advance Access
INTRO AMI. INTEGRILIN AND. REDUCED DOSE. OF THROMBOLYTIC IN. ACUTE
Effect of Additional Temporary Glycoprotein IIb-IIIa Receptor Inhibition on Troponin Release in Elective Percutaneous Coronary Interventions After Pretreatment.
ESPRIT INTEGRITI TACTICS Rate of Increase in DSA
Dye strongly persistent
Presentation transcript:

Intra Coronary AdjunctivE Tenecteplase During Primary PCI for STEMI: A Randomized, Open-Label, Placebo Controlled Pilot Study To Evaluate The Feasibility And Safety Of Low-Dose Intracoronary Tenecteplase vs. IC Saline Placebo Administered as Adjunctive Therapy To Aspirin, Clopidogrel, And Glycoprotein IIb/IIIa Inhibition During Primary PCI For STEMI. Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.; Priyamvada Singh, M.B.B.S.; Jianping Guo; Samer Kazziha, M.D.; Chandan Devireddy, M.D.; Duane Pinto, M.D. M.P.H; J. Jeffrey Marshall, M.D.; George Stouffer, M.D.; Kreton Mavromatis, M.D.; Laura Grip; Eugene Braunwald, M.D.; and C. Michael Gibson M.S., M.D. on behalf of the ICE T TIMI 49 Investigators An Investigator Initiated Trial Funded by a Research Grant from Genentech Inc.

BACKGROUND Distal Embolization During Primary PCI Embolization During Diagnostic Angiography Distal Vessel Cut Off and Stain of Myocardium Despite Excellent Result Upstream in Coronary Artery

The Goal is to Restore Both Normal Epicardial & Normal Myocardial Blood Flow 7.0% 3.7% Mortality (%) n = 487 n = 328 Epicardial TIMI Grade 3 Flow Epicardial TIMI Grade 2 / 1 / 0 Flow 7.5% 5 way p = 0.007 5.4% 4.7% Mortality (%) 2.9% 0.7% n = 64 n = 226 n = 136 n = 34 n = 279 Myocardial Perfusion Grade 3 Myocardial Perfusion Grade 2 Myocardial Perfusion Grades 0/1 Myocardial Perfusion Grade 3 Myocardial Perfusion Grades 2/1/0 Gibson et al, Circulation 2000 3

GOAL Evaluate the feasibility and safety of low-dose IC tenecteplase (TNK) administration as adjunctive therapy to aspirin, clopidogrel, and glycoprotein IIb/IIIa inhibition during primary PCI (PPCI).

TRIAL ORGANIZATION Trial Leadership: TIMI Study Group Chairman: Eugene Braunwald; Principal Investigator: C. Michael Gibson Project Director: Laura Grip; Statistician: Satishkumar Mohanavelu Data Safety Monitoring Board Jeffrey J. Popma, M.D. Enrolling Sites Principal Investigator Research Coordinator Number of Patients Dr. Samer Kazziha Elias Boueiri n=13 Dr. Chandan Devireddy Joanna Duncan n=11 Dr. Duane Pinto Jenifer Kaufman n=6 Dr. J. Jeffrey Marshall Ki-Ling Suen n=5 Dr. George Stouffer Carl Schuler n=3 Dr. Kreton Mavromatis Pamela Hyde n=2

STEMI < 6 hours for 1° PCI ASA 160-325 mg Clopidogrel 300-600 mg UFH Glycoprotein IIb/IIIa inhibitor TIMI 0/1 Flow in Culprit Artery R Advance wire and balloon without crossing lesion or withdrawing wire Study Drug - IC tenecteplase 4 mg bolus Study Drug - IC saline 4 mL bolus 2 min 2 min Angiography of culprit artery to assess percent stenosis, thrombus burden, epicardial flow and myocardial perfusion Check ACT (200-225 sec) UFH if necessary PCI Advance wire and balloon across lesion Study Drug - IC tenecteplase 4 mg bolus Study Drug - IC saline 4 mL bolus 2 min 2 min Angiography of culprit artery to assess epicardial flow and myocardial perfusion

PRIMARY EFFICACY ENDPOINT: Quantitative Coronary Analysis Primary Endpoint: The percent diameter stenosis of the culprit artery following the first administration of tenecteplase bolus vs placebo. 85% 93%

SECONDARY EFFICACY ENDPOINTS Corrected TIMI Frame Count (CTFC) Rate of restoring patency following IC bolus Rates of TIMI Myocardial Perfusion Grade Change in thrombus grade following first tenecteplase bolus

SAFETY ENDPOINTS - TIMI Major bleeding - TIMI Minor bleeding - TIMI Significant bleeding - Stroke through 30 days - ICH through 30 days - Cardiac arrhythmias

BASELINE CHARACTERISTICS IC Tenecteplase N = 18 Placebo N = 16 P-Value Age, mean (SD) 54.0 (±7.5) 55.9 (±9.3) NS Sex, male 14 (77.8%) 13 (81.3%) Prior PCI 3 (16.7%) 2 (12.5%) Diabetes 2 (11.1%) 3 (18.8%) Hypertension 12 (66.7%) 6 (35.5%) Prior MI 1 (6.3%) Hyperlipidemia 9 (50.0%) 6 (37.5%) Prior angina 7 (41.2%) Smoker within past year 12 (75.0%) 10 (55.6%)

PRIMARY EFFICACY END POINT: PERCENT DIAMETER STENOSIS OF THE CULPRIT LESION AFTER FIRST ADMINISTRATION OF STUDY DRUG AND OTHER SECONDARY ENDPOINTS IC Tenecteplase N = 18 Placebo N = 16 P-Value Percent Diameter Stenosis, (SD) 89.5% (±12.5) 93.7% (±10.5) NS Change in Percent Stenosis, (SD) -6.4% (±9.4) -1.9% (±4.4) CTFC 100.0 (60.0,100.0) 100.0 (100.0,100.0) TFG 2/3 9 (50.0%) 4 (25.0%) TMPG 2/3 2 (14.3%) Decrease in Thrombus Grade 8 (44.4%) 2 (12.5%) 0.041

POST-PCI ANGIOGRAPHIC CHARACTERISTICS (BEFORE SECOND BOLUS) IC Tenecteplase N = 18 Placebo N = 16 P-Value CTFC 26.00 (21.0,33.0) 16.00 (12.0,24.0) 0.050 CTFC <14 1 (8.3%) 5 (38.5%) 0.087 TFG 2/3 15 (100.0%) NS TMPG 2/3 8 (61.5%) 10 (71.4%)

% Patients with CTFC < X axis POST-PCI CORRECTED TIMI FRAME COUNT BY TREATMENT GROUP (Cumulative Distribution Function) p=0.05 % Patients with CTFC < X axis CTFC Frames

POST-SECOND BOLUS ANGIOGRAPHIC CHARACTERISTICS IC Tenecteplase N = 18 Placebo N = 16 P-Value CTFC 29.0 (23.0,43.0) 20.0 (14.0,30.0) NS CTFC <14 2 (12.5%) 1 (7.69%) TFG 2/3 16 (94.1%) 15 (100.0%) TMPG 2/3 9 (56.3%) 11 (73.3%)

SAFETY: BLEEDING IC Tenecteplase N = 18 Placebo N = 16 P-Value TIMI Major Bleeds 0.0% (0) N/A TIMI Minor Bleeds 27.8% (5) 6.3% (1) 0.180 TIMI Minimal Bleeds 22.2% (4) 12.5% (2) 0.660 TIMI Major or Minor Bleeds Transfusion of PRBC 5.6% (1) 1.000 Thrombocytopenia 26.7% (4) 0.033 Stroke Intracranial Hemorrhage (ICH)

LIMITATIONS Small sample size limits definitive conclusions regarding efficacy and safety Time needed for study drug to act when administered via intra-coronary route was assumed to be within two minutes

CONCLUSIONS Compared with IC placebo, IC TNK administration did not improve the pre-PCI percent stenosis, but did improve pre-PCI thrombus burden. There was more post-PCI hyperemia following placebo administration, perhaps reflecting greater distal embolization.